Drug Trial Radar · NCT05562362
Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension
Last checked: Nov 20, 2026Latest source record: Sep 30, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Jun 18, 2020
Primary completion
Nov 12, 2020
Study completion Nov 12, 2020
Sponsor
- Lead sponsor
- Travere Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This single-center, open-label, randomized, single and multiple-dose, 3-way sequential study at 3 dose levels will be performed in healthy subjects. Subjects will be randomized to 1 of the 3 dose levels. In each dose level, subjects will be administered a single dose in the fasted state and then a single dose in the fed state, followed by 14 days of dosing to assess Pharmacokinetics (PK) following multiple dosing.
Conditions
- Healthy Subjects
Interventions
RE-021, sparsentanDrug
RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of single-dose pharmacokinetics of sparsentan oral suspension dosed in fed and fasted states - CmaxTime frame: Study Days 1 and 8
- Assessment of single-dose pharmacokinetics of sparsentan oral suspension dosed in fed and fasted states - AUC(0-last)Time frame: Study Days 1 and 8
- Assessment of single-dose pharmacokinetics of sparsentan oral suspension dosed in fed and fasted - states - AUC(0-inf)Time frame: Study Days 1 and 8
- Food effect on pharmacokinetics of sparsentan oral suspension dosed after standard high-fat - breakfast - CmaxTime frame: Study Days 1 and 8
- Food effect on pharmacokinetics of sparsentan oral suspension dosed after standard high-fat - breakfast - AUC(0-last)Time frame: Study Days 1 and 8
- Food effect on pharmacokinetics of sparsentan oral suspension dosed after standard high-fat breakfast - AUC(0-inf)Time frame: Study Days 1 and 8
- Multiple-dose pharmacokinetics of a sparsentan oral suspension dosed in the fed state - CmaxTime frame: Study Days 12 to 28
- Multiple-dose pharmacokinetics of a sparsentan oral suspension dosed in the fed state - AUC(0-24)Time frame: Study Days 12 to 28
- Multiple-dose pharmacokinetics of a sparsentan oral suspension dosed in the fed state - TCP (AUC(0-24)/AUC(0-inf)Time frame: Study Days 12 to 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Travere Investigational Site
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.